Source:http://linkedlifedata.com/resource/pubmed/id/18539537
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2008-8-18
|
pubmed:abstractText |
Interferon-beta (IFN-beta) is an effective treatment for a subgroup of patients with multiple sclerosis (MS). The mechanism of action as well as the pathophysiological basis of responsiveness to IFN-beta is not well understood. To improve treatment considerations in MS patients predictive markers for response to IFN-beta therapy at early timepoints are needed. Here we correlated changes in serum cytokine levels (IL-13, IL-10, IL-5, IL-4, IFN-gamma) with the clinical response to IFN-beta treatment. Serum cytokine levels of 77 untreated and 43 IFN-beta treated relapsing-remitting MS patients (RRMS) were measured by ELISA, including longitudinal measurements in 17 patients. We found a significant upregulation of IL-10 and IL-5 serum cytokine levels during IFN-beta therapy. However, clinical response was only associated with IL-10 serum levels (p=0.038; positive predictive value 0.95, negative predictive value 0.43) but not with IL-5. The predictive power was increased by a combined testing of IL-10 with expression of co-signaling molecules on monocytes, that were previously shown to change during IFN-beta therapy. In a subgroup of 17 patients testing of 4 markers had a positive and negative predictive value of 1.0 for at least 2 of these markers being positive in treatment responders. The results suggest that serum IL-10 is useful to predict treatment response to IFN-beta particularly in combination with a panel of other IFN-beta dependent parameters.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD40,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD86,
http://linkedlifedata.com/resource/pubmed/chemical/Cytokines,
http://linkedlifedata.com/resource/pubmed/chemical/Intercellular Signaling Peptides...,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-beta,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-10,
http://linkedlifedata.com/resource/pubmed/chemical/PDCD1LG2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Programmed Cell Death 1 Ligand 2...
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
1521-7035
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
128
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
306-13
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:18539537-Adult,
pubmed-meshheading:18539537-Antigens, CD,
pubmed-meshheading:18539537-Antigens, CD40,
pubmed-meshheading:18539537-Antigens, CD86,
pubmed-meshheading:18539537-Cytokines,
pubmed-meshheading:18539537-Female,
pubmed-meshheading:18539537-Humans,
pubmed-meshheading:18539537-Intercellular Signaling Peptides and Proteins,
pubmed-meshheading:18539537-Interferon-beta,
pubmed-meshheading:18539537-Interleukin-10,
pubmed-meshheading:18539537-Male,
pubmed-meshheading:18539537-Middle Aged,
pubmed-meshheading:18539537-Monocytes,
pubmed-meshheading:18539537-Multiple Sclerosis,
pubmed-meshheading:18539537-Programmed Cell Death 1 Ligand 2 Protein,
pubmed-meshheading:18539537-Up-Regulation
|
pubmed:year |
2008
|
pubmed:articleTitle |
Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis.
|
pubmed:affiliation |
Department of Neurology, Medical School Hannover, Carl-Neuberg-Str 1, 30625 Hannover, Germany. wiesemann.elke@mh-hannover.de
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|